



NDA 19949/S-067  
NDA 20090/S-048

## SUPPLEMENT APPROVAL

Pfizer, Inc.  
Attention: Michele Burtness  
Senior Manager, Pfizer Essential Health Global Regulatory Affairs Brands  
235 East 42<sup>nd</sup> Street  
New York, NY 10017

Dear Ms. Burtness:

Please refer to your Supplemental New Drug Applications (sNDAs) dated August 25, 2017, received August 25, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA 19949/S-067 Diflucan (fluconazole) Tablets  
NDA 20090/S-048 Diflucan (fluconazole) Powder for Oral Suspension

These Prior Approval supplemental new drug applications provide for changes to the **CLINICAL PHARMACOLOGY** section, **Microbiology** subsection, and **REFERENCES** section of the labeling.

### **APPROVAL & LABELING**

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301)796-0797.

Sincerely,

*{See appended electronic signature page}*

Dmitri Iarikov, MD, PhD  
Acting Deputy Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

DMITRI IARIKOV  
10/27/2017